Definitive Healthcare (NASDAQ:DH – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06, FiscalAI reports. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.The company had revenue of $61.53 million for the quarter, compared to the consensus estimate of $59.57 million. Definitive Healthcare updated its FY 2026 guidance to 0.140-0.170 EPS and its Q1 2026 guidance to 0.030-0.030 EPS.
Here are the key takeaways from Definitive Healthcare’s conference call:
- Definitive reported Q4 results that were at or above the high end of guidance with $61.5M revenue (down 1% YoY) and $18.1M adjusted EBITDA (29% margin), and generated about $55M of unlevered free cash flow on a trailing 12‑month basis.
- The company says it has remediated the claims data disruption—bringing claims volumes back to above historical levels—and expanded core data assets (including added mobile phone data) to strengthen its proprietary dataset.
- Integration and product work accelerated in 2025 (new connectors with Snowflake, Databricks, HubSpot and a PhysicianView/Salesforce pilot), shortening integration time by ~25% and adding over 60 integrated customers in Q4 to improve stickiness.
- Retention trends are mixed: gross dollar retention improved ~2 points YoY and renewal rates rose modestly in recent quarters, but net dollar retention declined due to weak upsell activity; management expects NDR to bottom in 2025 and to modestly recover in 2026.
- 2026 guidance assumes continued top‑line pressure with full‑year revenue of $220M–$226M (down 6%–9% YoY) even as management plans targeted R&D and go‑to‑market investments while preserving a 24%–26% adjusted EBITDA margin.
Definitive Healthcare Stock Performance
Shares of Definitive Healthcare stock traded down $0.01 during trading on Thursday, reaching $1.40. The company’s stock had a trading volume of 753,013 shares, compared to its average volume of 372,979. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41. The firm has a market cap of $197.91 million, a PE ratio of -0.84 and a beta of 1.59. Definitive Healthcare has a 52 week low of $1.36 and a 52 week high of $5.22. The business’s 50-day moving average price is $2.21 and its 200-day moving average price is $2.89.
Analysts Set New Price Targets
View Our Latest Research Report on DH
Institutional Trading of Definitive Healthcare
Several large investors have recently modified their holdings of DH. Goldman Sachs Group Inc. grew its stake in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after buying an additional 7,404,363 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Definitive Healthcare during the second quarter worth $4,247,000. Inspire Investing LLC increased its holdings in Definitive Healthcare by 505.7% in the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after purchasing an additional 583,562 shares in the last quarter. Millennium Management LLC increased its stake in shares of Definitive Healthcare by 230.9% in the fourth quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock valued at $953,000 after buying an additional 231,743 shares during the period. Finally, Jane Street Group LLC raised its stake in shares of Definitive Healthcare by 212.4% during the second quarter. Jane Street Group LLC now owns 328,410 shares of the company’s stock valued at $1,281,000 after acquiring an additional 223,296 shares during the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Definitive Healthcare
Here are the key news stories impacting Definitive Healthcare this week:
- Positive Sentiment: Cash position strengthened — cash and cash equivalents rose to about $163.6M (up ~55% YoY), providing a larger liquidity buffer. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
- Positive Sentiment: Revenue roughly in line with expectations — Q4 revenue was about $61.5M, essentially flat YoY and slightly above some estimates, showing demand stability for the data/analytics business. Definitive Healthcare Q4 2025 Press Release / Slide Deck
- Neutral Sentiment: Company filed full Q4 release, slide deck and hosted a conference call — useful for details on customer trends and cost initiatives; review management commentary for color. Q4 Slide Deck / Conference Call
- Negative Sentiment: Guidance disappointed — Q1 EPS guided to $0.03 (vs. consensus ~$0.05) and FY‑2026 EPS guided to $0.14–0.17 (vs. consensus ~$0.21); revenue guidance of $220M–$226M also trails estimates, a main driver of the downward move. Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
- Negative Sentiment: Profitability metrics mixed/worse in some reports — one summary shows operating loss widening and a larger net loss / diluted EPS miss (Quiver reports diluted EPS -$0.09 and wider losses), which weighed on sentiment; note some sources reported a $0.06 EPS beat — check the company release and call transcript for reconciliation. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
- Negative Sentiment: Institutional selling visible — several large funds reduced or exited positions in Q4 (e.g., Palisade, Goldman, NY State Pension), which can amplify downward pressure near-term. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
Definitive Healthcare Company Profile
Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.
The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.
Further Reading
- Five stocks we like better than Definitive Healthcare
- The Man Who Predicted the iPhone Says Buy These 3 Companies
- Unlocked: Elon Musk’s Next Big IPO
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- This makes me furious
- The free stock picks nobody’s talking about
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
